Better predict pharmacokinetic (PK) and drug-drug interactions (DDIs) with DMPK/ADME studies and computational modeling on your compound, prior to clinical trials, to move quickly from discovery to development.
WANT QUICK PK ANSWERS?
Fast starts. While study schedule openings last.
Are you looking for definitive pharmacokinetic (PK) data to meet your year-end goals, so that you can be ready to move your candidates forward quickly in the new year? We’ve ramped up and have a number of new study slots available in our schedule for definitive PK study work that can start now through December 31, 2022. If you can take advantage of completing one or more PK studies yet this year, and are ready to move fast, contact your Labcorp representative or email today for more details.
Drug-Drug Interaction (DDI) sample analysis
Toxicology (TK) / safety sample analysis
Dose range finding (DRF) sample analysis
Pharmacology (PK) sample analysis
Dried Blood Spot (DBS) sample analysis
OPPTS 870.7600: Dermal penetration
Human pharmacokinetics (PK) prediction
Population pharmacokinetic (PopPK) modeling
Physiologically based pharmacokinetics (PBPK) modeling
Quantitative and/or systems pharmacology (QSP/SP) modeling
Drug-Drug Interaction (DDI) modeling
In vitro cytochrome (CYP) induction
Compartmental & non-compartmental PK/TK analysis
Screening pharmacokinetics (fast PK)
Bioavailability, bioequivalence and biosimilars modeling
Consider the integration possibilities between your preclinical and clinical studies
As an integrated preclinical & clinical CRO, we can offer you connected insights between your nonclinical pharmacology work and your clinical pharmacology studies and clinical trials.
For example, some PBPK pharmacometrics have been accepted in lieu of clinical DDI studies.
Let's start a conversation
Contact Us
Labcorp is a leading global life sciences company that includes contract research and developmental services to the pharmaceutical, medical technology, crop protection and chemical industries.
.png){kind=icon}